MYCAPSSA

This brand name is authorized in Austria, Estonia, Croatia, Ireland, Italy, Lithuania, Poland, United States

Active ingredients

The drug MYCAPSSA contains one active pharmaceutical ingredient (API):

1 Octreotide UNII 75R0U2568I - OCTREOTIDE ACETATE

Octreotide is a synthetic octapeptide derivative of naturally occurring somatostatin with similar pharmacological effects, but with a considerably prolonged duration of action. It inhibits pathologically increased secretion of growth hormone (GH) and of peptides and serotonin produced within the GEP endocrine system. Read about Octreotide

Medication package inserts

Below package inserts are available for further reading:

Title	Information Source	Document Type
MYCAPSSA Gastro-resistant hard capsule	European Medicines Agency (EU)	MPI, EU: SmPC

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC code	Group title	Classification
H01CB02	Octreotide	H Systemic hormonal preparations, excl. Sex hormones and insulins → H01 Pituitary and hypothalamic hormones and analogues → H01C Hypothalamic hormones → H01CB Somatostatin and analogues
Discover more medicines within H01CB02

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
Country: EE	Ravimiamet	Identifier(s): 3040917
Country: IT	Agenzia del Farmaco	Identifier(s): 050456019
Country: LT	Valstybinė vaistų kontrolės tarnyba	Identifier(s): 1096045
Country: US	FDA, National Drug Code	Identifier(s): 69880-120